A carregar...
Potential repurposing of the HDAC inhibitor valproic acid for patients with COVID-19
There is a need for therapeutic approaches to prevent and mitigate the effects of Coronavirus Disease (2019) (COVID-19). The histone deacetylase (HDAC) inhibitor valproic acid, which has been available for the therapy of epilepsy for many years, is a drug that could be repurposed for patients with s...
Na minha lista:
| Publicado no: | Eur J Pharmacol |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Elsevier B.V.
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7923868/ https://ncbi.nlm.nih.gov/pubmed/33667455 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejphar.2021.173988 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|